A Rapamycin-Based GMP-Compatible Process for the Isolation and Expansion of Regulatory T Cells for Clinical Trials

A Rapamycin-Based GMP-Compatible Process for the Isolation and Expansion of Regulatory T Cells for Clinical Trials

The concept of regulatory T cell (Treg)-based immunotherapy has enormous potential for facilitating tolerance in autoimmunity and transplantation. Clinical translation of Treg cell therapy requires production processes that satisfy the rigors of Good Manufacturing Practice (GMP) standards. In this r...

Full description

Bibliographic Details
Main Authors: Henrieta Fraser, Niloufar Safinia, Nathali Grageda, Sarah Thirkell, Katie Lowe, Laura J. Fry, Cristiano Scottá, Andrew Hope, Christopher Fisher, Rachel Hilton, David Game, Paul Harden, Andrew Bushell, Kathryn Wood, Robert I. Lechler, Giovanna Lombardi
Format: Article
Language:English
Published: Elsevier 2018-03-01
Series:Molecular Therapy: Methods & Clinical Development
Subjects:
Tregs
GMP process
clinical trials
cell therapy
ONE study
solid organ transplantation
Online Access:http://www.sciencedirect.com/science/article/pii/S232905011830007X

Internet

http://www.sciencedirect.com/science/article/pii/S232905011830007X

Similar Items